Gensight Biologics Sa(GSGTF)

Description: GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye, and central nervous system. The company develops its products through gene therapy-based approach with technology platforms of mitochondrial targeting sequence and optogenetics. Its lead product candidates include GS010, an AAV2 containing the human wild-type ND4 gene, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy associated with mutation in the ND4 gene; and GS030 that comprises a gene encoding photoactivatable channelrhodopsin for the treatment of reinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company also develops products that are preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.

---

Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Gene Therapy Genetics Macular Degeneration Ophthalmic Neurodegenerative Diseases Degenerative Disease Senescence Neurodegenerative Disease Dry Age Related Macular Degeneration 4 G Leber's Hereditary Optic Neuropathy Atrophy Hereditary Optic Neuropathy Mitochondrial And Neurodegenerative Diseases Mutation Nd4 Ophthalmic And Neurodegenerative Diseases Therapies For Mitochondrial And Neurodegenerative Diseases

---

Home Page: www.gensight-biologics.com

74, rue du Faubourg Saint-Antoine
Paris, 75012
France
Phone: 33 1 76 21 72 20

---

Officers

Exchange: PINK

Country: US

Currency: US Dollar ($)